- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
|International Nonproprietary Names|
|RG-7221 | RG7221 | RO5520985|
|Vanucizumab is an investigational bi-specific monoclonal antibody, with potential anti-neoplastic activity being developed by Hoffmann-La Roche [1-2]. Vanucizumab simultaneously targets angiopoietin 2 (ANGPT2) and vascular endothelial growth factor A (VEGFA).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST seuqence analysis reveals 100% matches with peptide sequences claimed in patent US8945552 and likely identify XMab1 and XMab2 as candidates for vanucizumab .
|GtoPdb PubChem SID||315661217|
|Search PubMed clinical trials||vanucizumab|
|Search PubMed titles||vanucizumab|
|Search PubMed titles/abstracts||vanucizumab|